278 research outputs found
Patient perception of treatment efficacy, disability and health satisfaction
Abstract published in Rheumatology, Volume 55 (Suppl 1), April 2016, page i123
Does health satisfaction and perception of treatment efficacy in patients with inflammatory arthritis correlate with disability and global health state?
A Significant Proportion of Patients With Newly Diagnosed and Established Inflammatory Arthritis Have Positive Doppler Signal in Their Hand Joints in the Context of Normal C-reactive Protein Levels
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies
The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed and nonlicensed) based on their proven efficacy in treating different clinical manifestations associated with psoriasis and PsA. This review presents the level of evidence of efficacy of different biologic treatments and small molecule inhibitors for certain clinical features of treatment of PsA and psoriasis, which was graded in categories I–IV. The literature searches were performed on the following classes of biologic agents and small molecules: TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), anti-IL12/IL23 (ustekinumab), anti-IL17 (secukinumab, brodalumab, ixekizumab), anti-IL6 (tocilizumab), T cell modulators (alefacept, efalizumab, abatacept, itolizumab), B cell depletion therapy (rituximab), phosphodiesterase 4 inhibitor (apremilast) and Janus kinase inhibitor (tofacitinib). A comprehensive table including 17 different biologic agents and small molecule inhibitors previously tested in psoriasis and PsA was generated, including the level of evidence of their efficacy for each of the clinical features included in our review (axial and peripheral arthritis, enthesitis, dactylitis, and nail and skin disease). We also proposed a limited set of recommendations for a sequential biologic treatment algorithm for patients with PsA who failed the first anti-TNF therapy, based on the available literature data. There is good evidence that many of the biologic treatments initially tested in psoriasis are also effective in PsA. Further research into both prognostic biomarkers and patient stratification is required to allow clinicians the possibility to make better use of the various biologic treatment options available. This review showed that there are many potentially new treatments that are not included in the current guidelines that can be used for selected categories of patients based on their disease phenotype, clinician experience and access to new biologic therapies
Tumour necrosis factor inhibitors used in the treatment of rheumatoid arthritis: Evidence of safety, efficacy and health implication
Rheumatoid arthritis (RA) is a systemic autoimmune condition characterised by inflammation and destruction of synovial joints. The pathogenesis of inflammation is underpinned by interaction and activation of immune cells, which release inflammatory cytokines such as tumour necrosis factor (TNF) and interleukins. These mechanisms of disease pathogenesis were targeted by specific drugs in the form of monoclonal antibodies (mAb) or soluble receptors. The advent of biological disease modifying therapies (bDMARDs) has revolutionised the management of RA. These agents dramatically reduce synovial inflammation, halt the progression of radiographic joint damage, and improve functional ability and health related quality of life outcomes. This has a positive impact on the socioeconomic burden of RA. This chapter reviews the pathogenesis of RA and evidence behind the use of TNF inhibitors licensed for RA treatment. We focus on clinical efficacy, safety profile and cost-effectiveness of infliximab, etanercept, adalimumab, certolizumab, golimumab. Additionally, we discuss national and international recommendations for the clinical use of TNF inhibitors, with further consideration of the financial implications. Examples of clinical randomised controlled trials (RCTs), which have proven the efficacy of different TNF inhibitors in RA are also included in this chapter. The use of TNF inhibitor biosimilars will be discussed in chapter 11
Biologic treatments (other than anti-TNF therapy) licensed for use in rheumatoid arthritis
Despite the huge progress made by the use of tumour necrosis factor (TNF) inhibitors in the treatment of rheumatoid arthritis (RA), there was still an unmet need for discovering and implementing new biologic therapies for RA patients who lost response or had side-effects to TNF inhibitors. The advances in molecular biology and understanding of the complex pathogenesis of RA enabled the identification of other pivotal molecules, whose blockage was associated with clinical benefits in RA. This chapter reviews the clinical efficacy, safety profile and cost-effectiveness of several biologic agents licensed for use in RA patients, which target different interleukins (IL), such as IL1 (anakinra) and IL6 (tocilizumab), or are associated with B cell depletion (rituximab), T cell co-stimulatory blockage (abatacept) and small molecule inhibition (tofacitinib). In addition, we discuss the national and international guidelines for use of these biologic agents in relation to the use of TNF inhibitors in patients with moderatesevere RA, providing examples of switching between various biologic therapies
New biologic agents and biosimilars developed for rheumatoid arthritis
The pathogenesis of rheumatoid arthritis (RA) is characterised by interactions between several types of immune cells, which are associated with the release of multiple inflammatory cytokines. Recently, numerous biologic treatments targeting classes of immune cells, cytokines or intra-cellular pathways of pro-inflammatory signals have been developed. Some of them are currently under research as potential therapeutic options for RA patients. This chapter reviews the available evidence regarding the safety and efficacy of new biologic agents targeting B cells, proinflammatory interleukins (IL), T helper 17 (Th17) pathway and intracellular enzymes. This chapter reviews the most relevant randomised controlled trials (RCTs) which have proven the efficacy of different biologic agents and small molecule inhibitors in controlling the inflammation associated with RA. The management of RA remains a dynamic and evolving field. The development of less expensive ‘biosimilar’ drugs, analogous to existing licensed biologic therapies, is an emerging area of research that deserves particular attention
Active Synovitis at the Wrist Level Detected by Doppler Ultrasound (Us) Is the Most Common Finding in Patients With Inflammatory Arthritis, Irrespective of Their Underlying Diagnosis – Results From a Cohort Study
Factors associated with oral specialist referral of patients with Sjögren’s syndrome in a rheumatology tertiary centre
- …